Background COVID‐19 can present with lymphopenia and extraordinary complex
multiorgan pathologies that can trigger long‐term sequela. Aims Given that inflammasome …

In recent decades, researchers around the world have been studying intensively how micro-
organisms that are present inside living organisms could affect the main processes of life …

COVID-19, caused by the SARS-CoV-2 virus, is a respiratory infectious disease. While most
patients recover after treatment, there is growing evidence that COVID-19 may result in …

The ongoing pandemic caused by the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has drawn the attention of researchers and clinicians from several disciplines …

Objectives To describe the clinical characteristics and predictors of major outcomes in
patients treated with tocilizumab (TCZ) for severe COVID-19 pneumonia. Patients and …

The outbreak of coronavirus disease 2019 (COVID-19) in December 2019 in Wuhan, China,
introduced the third highly pathogenic coronavirus into humans in the 21st century. Scientific …

Several medicinal products for human use are currently under consideration as potential
treatment for COVID-19 pandemic. As proposals cover also prophylactic use, the treatment …

Despite the international scientific community's commitment to improve clinical knowledge
about coronavirus disease 2019 (COVID‐19), knowledge regarding molecular details …

The newfound coronavirus disease 2019 (COVID-19), initiated by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), is an international public health concern …

Background COVID‐19 pandemic causes high global morbidity and mortality and better
medical treatments to reduce mortality are needed. Objective To determine the added …